Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively

被引:102
作者
Eickmann, Markus [1 ]
Gravemann, Ute [2 ]
Handke, Wiebke [2 ]
Tolksdorf, Frank [3 ]
Reichenberg, Stefan [3 ]
Mueller, Thomas H. [2 ]
Seltsam, Axel [2 ]
机构
[1] Philipps Univ Marburg, Inst Virol, Marburg, Germany
[2] German Red Cross Blood Serv NSTOB, Springe, Germany
[3] Macopharma Int GmbH, Langen, Germany
关键词
PATHOGEN REDUCTION; TRYPANOSOMA-CRUZI; BLOOD COMPONENTS; SYSTEM; EPIDEMIOLOGY; TECHNOLOGY; INFECTION; EFFICACY; UPDATE; SAFETY;
D O I
10.1111/trf.14652
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
BACKGROUNDEbola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have been identified as potential threats to blood safety. This study investigated the efficacy of the THERAFLEX UV-Platelets and THERAFLEX MB-Plasma pathogen inactivation systems to inactivate EBOV and MERS-CoV in platelet concentrates (PCs) and plasma, respectively. STUDY DESIGN AND METHODSPCs and plasma were spiked with high titers of cell culture-derived EBOV and MERS-CoV, treated with various light doses of ultravioletC (UVC; THERAFLEX UV-Platelets) or methylene blue (MB) plus visible light (MB/light; THERAFLEX MB-Plasma), and assessed for residual viral infectivity. RESULTSUVC reduced EBOV (4.5 log) and MERS-CoV (3.7 log) infectivity in PCs to the limit of detection, and MB/light decreased EBOV (4.6 log) and MERS-CoV (3.3 log) titers in plasma to nondetectable levels. CONCLUSIONSBoth THERAFLEX UV-Platelets (UVC) and THERAFLEX MB-Plasma (MB/light) effectively reduce EBOV and MERS-CoV infectivity in platelets and plasma, respectively.
引用
收藏
页码:2202 / 2207
页数:6
相关论文
共 32 条
[1]
[Anonymous], 2010, GES 2005 RICHTL
[2]
Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro [J].
Cap, Andrew P. ;
Pidcoke, Heather F. ;
Keil, Shawn D. ;
Staples, Hilary M. ;
Anantpadma, Manu ;
Carrion, Ricardo, Jr. ;
Davey, Robert A. ;
Frazer-Abel, Ashley ;
Taylor, Audra L. ;
Gonzales, Richard ;
Patterson, Jean L. ;
Goodrich, Raymond P. .
TRANSFUSION, 2016, 56 :S6-S15
[3]
Castro E, 2008, VOX SANG, V95, P290
[4]
The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets [J].
Castro, Emma ;
Miguel Gonzalez, Luis ;
Miguel Rubio, Jose ;
Ramiro, Raquel ;
Girones, Nuria ;
Montero, Estrella .
TRANSFUSION, 2014, 54 (09) :2207-2216
[5]
Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection [J].
Corman, Victor M. ;
Albarrak, Ali M. ;
Omrani, Ali Senosi ;
Albarrak, Mohammed M. ;
Farah, Mohamed Elamin ;
Almasri, Malak ;
Muth, Doreen ;
Sieberg, Andrea ;
Meyer, Benjamin ;
Assiri, Abdullah M. ;
Binger, Tabea ;
Steinhagen, Katja ;
Lattwein, Erik ;
Al-Tawfiq, Jaffar ;
Mueller, Marcel A. ;
Drosten, Christian ;
Memish, Ziad A. .
CLINICAL INFECTIOUS DISEASES, 2016, 62 (04) :477-483
[6]
Inter-strand photoproducts are produced in high yield within A-DNA exposed to UVC radiation [J].
Douki, T ;
Laporte, G ;
Cadet, J .
NUCLEIC ACIDS RESEARCH, 2003, 31 (12) :3134-3142
[7]
Identification of a novel coronavirus in patients with severe acute respiratory syndrome [J].
Drosten, C ;
Günther, S ;
Preiser, W ;
van der Werf, S ;
Brodt, HR ;
Becker, S ;
Rabenau, H ;
Panning, M ;
Kolesnikova, L ;
Fouchier, RAM ;
Berger, A ;
Burguière, AM ;
Cinatl, J ;
Eickmann, M ;
Escriou, N ;
Grywna, K ;
Kramme, S ;
Manuguerra, JC ;
Müller, S ;
Rickerts, V ;
Stürmer, M ;
Vieth, S ;
Klenk, HD ;
Osterhaus, ADME ;
Schmitz, H ;
Doerr, HW .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (20) :1967-1976
[8]
PLATELET CONCENTRATES IN AN ADDITIVE SOLUTION PREPARED FROM POOLED BUFFY COATS - INVIVO STUDIES [J].
ERIKSSON, L ;
SHANWELL, A ;
GULLIKSSON, H ;
HOGMAN, CF ;
SVENSSON, LA ;
KRISTENSEN, J ;
BERG, B .
VOX SANGUINIS, 1993, 64 (03) :133-138
[9]
Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light [J].
Faddy, Helen M. ;
Fryk, Jesse J. ;
Prow, Natalie A. ;
Watterson, Daniel ;
Young, Paul R. ;
Hall, Roy A. ;
Tolksdorf, Frank ;
Sumian, Chryslain ;
Gravemann, Ute ;
Seltsam, Axel ;
Marks, Denese C. .
TRANSFUSION, 2016, 56 (06) :1548-1555
[10]
Clinical recognition and management of patients exposed to biological warfare agents [J].
Franz, DR ;
Jahrling, PB ;
Friedlander, AM ;
McClain, DJ ;
Hoover, DL ;
Bryne, WR ;
Pavlin, JA ;
Christopher, CW ;
Eitzen, EM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (05) :399-411